Wells Fargo & Company MN Has $4.30 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Wells Fargo & Company MN trimmed its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 61.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 250,561 shares of the biotechnology company's stock after selling 397,714 shares during the period. Wells Fargo & Company MN owned 0.11% of ADMA Biologics worth $4,297,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in ADMA Biologics by 1.3% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock valued at $865,000 after purchasing an additional 645 shares during the period. Oregon Public Employees Retirement Fund raised its stake in ADMA Biologics by 1.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after purchasing an additional 700 shares during the last quarter. Mutual of America Capital Management LLC boosted its holdings in ADMA Biologics by 2.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock valued at $614,000 after purchasing an additional 751 shares during the period. Maryland State Retirement & Pension System lifted its stake in shares of ADMA Biologics by 1.1% in the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock valued at $1,365,000 after buying an additional 897 shares during the period. Finally, GAMMA Investing LLC grew its position in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after buying an additional 967 shares in the last quarter. Institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA traded down $0.47 during midday trading on Friday, reaching $21.86. 2,611,436 shares of the company traded hands, compared to its average volume of 3,636,536. ADMA Biologics, Inc. has a 12 month low of $6.40 and a 12 month high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock's 50-day simple moving average is $18.80 and its 200-day simple moving average is $18.28. The firm has a market cap of $5.17 billion, a PE ratio of 78.07 and a beta of 0.53.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.